Praxis Precision Medicines Inc. released a corporate presentation highlighting its late-stage CNS pipeline and key clinical and regulatory milestones. The company discussed ulixacaltamide for essential tremor, supported by two positive Phase 3 Essential3 studies and an NDA submission, as well as relutrigine for SCN2A/SCN8A developmental and epileptic encephalopathies (DEEs), including Breakthrough Therapy Designation and an NDA submission. The presentation also covered elsunersen, an intrathecal antisense oligonucleotide for SCN2A gain-of-function DEE, and vormatrigine for focal and generalized epilepsy, including ongoing POWER studies and positioning within its broader epilepsy development program. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on February 19, 2026, and is solely responsible for the information contained therein.